Arix Bioscience (DB:3HY) - Stock Price, News & Analysis

3HY Stock Overview

3HY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (11.8x) is below the German market (16.1x)

Became profitable this year

Risk Analysis

Earnings have declined by 16.4% per year over past 5 years

Arix Bioscience plc Competitors

Deutsche Balaton

HMSE:BBHK

€175.4m

MPC Münchmeyer Petersen Capital

XTRA:MPCK

€197.4m

Deutsche Beteiligungs

XTRA:DBAN

€420.9m

Quirin Privatbank

XTRA:QB7

€161.5m

Price History & Performance

Summary of all time highs, changes and price drops for Arix Bioscience
Historical stock prices
Current Share Price	UK£1.61
52 Week High	UK£1.67
52 Week Low	UK£1.09
Beta	1.05
11 Month Change	8.05%
3 Month Change	33.06%
1 Year Change	28.80%
33 Year Change	-33.47%
5 Year Change	-11.54%
Change since IPO	-32.47%

Recent updates

Shareholder Returns

	3HY	DE Capital Markets	DE Market
7D	-3.6%	-0.2%	-0.02%
1Y	28.8%	26.3%	8.2%

Return vs Industry: 3HY exceeded the German Capital Markets industry which returned 6.2% over the past year.

Return vs Market: 3HY exceeded the German Market which returned -1.4% over the past year.

Price Volatility

Is 3HY's price volatile compared to industry and market?
3HY volatility
3HY Average Weekly Movement	5.9%
Capital Markets Industry Average Movement	4.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 3HY has not had significant price volatility in the past 3 months.

Volatility Over Time: 3HY's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	9	n/a	arixbioscience.com

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally.

Arix Bioscience plc Fundamentals Summary

How do Arix Bioscience's earnings and revenue compare to its market cap?
3HY fundamental statistics
Market cap	€206.79m
Earnings (TTM)	€17.52m
Revenue (TTM)	€16.59m

11.8x

P/E Ratio

12.5x

P/S Ratio

Is 3HY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3HY income statement (TTM)
Revenue	UK£14.16m
Cost of Revenue	UK£0
Gross Profit	UK£14.16m
Other Expenses	-UK£799.00k
Earnings	UK£14.96m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.12
Gross Margin	100.00%
Net Profit Margin	105.64%
Debt/Equity Ratio	0%

How did 3HY perform over the long term?

See historical performance and comparison

3HY Stock Overview

Rewards

Risk Analysis

Arix Bioscience plc Competitors

HMSE:BBHK

€175.4m

XTRA:MPCK

€197.4m

XTRA:DBAN

€420.9m

XTRA:QB7

€161.5m

Price History & Performance

Recent News & Updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Investor sentiment improves as stock rises 16%

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought €79k worth of stock

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Investor sentiment improves as stock rises 16%

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought €79k worth of stock

New minor risk - Share price stability

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought €87k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought €243k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Less than half of directors are independent

Independent Non-Executive Chairman recently bought €90k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings released: UK£0.48 loss per share (vs UK£0.97 profit in FY 2020)

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Less than half of directors are independent

Investor sentiment improved over the past week

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day high: €2.36

Executive Chairman recently bought €416k worth of stock

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: €1.82

Market bids up stock over the past week

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: €1.70

New 90-day high: €1.16

New 90-day high - €1.08

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

Shareholder Returns

Price Volatility

About the Company

Arix Bioscience plc Fundamentals Summary

11.8x

12.5x

Earnings & Revenue